Claims for Patent: 6,004,944

Summary for Patent: 6,004,944

Title:	Protein delivery by secretory gland expression
Abstract:	Secretory gland cells, particularly pancreatic, hepatic, and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the bloodstream to obtain therapeutic levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term or short term therapies for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.
Inventor(s):	Rothman; Stephen S. (Berkeley, CA), Goldfine; Ira D. (Kentfield, CA), German; Michael S. (San Francisco, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	08/942,939
Patent Claims:	1. A method of reducing blood glucose levels in a diabetic mammalian subject, the method comprising: introducing into the pancreas of the mammalian subject a construct comprising an insulin-encoding DNA and a promoter sequence operably linked to the insulin-encoding DNA to facilitate expression in a eukaryotic cell, said introducing being by intraductal administration; wherein expression of the introduced construct in the pancreas occurs such that a biologically active insulin polypeptide is delivered into the bloodstream of the patient in a therapeutically effective amount, and blood glucose levels in the mammalian subject are reduced. 2. The method of claim 1, wherein a euglycemic state is maintained for at least three days. 3. The method of claim 1, wherein a euglycemic state is maintained for at least 6 days. 4. The method of claim 1, the method further comprising enhancing delivery of the insulin polypeptide to the bloodstream by administration of a cholinergic agonist to the mammalian subject. 5. The method of claim 1, the method further comprising enhancing delivery of the insulin polypeptide into the bloodstream by ingestion of a meal by the mammalian subject. 6. A method of delivering a desired polypeptide to a mammalian subject, the method comprising: introducing in vivo into a lumen of a duct of a salivary gland and into a lumen of a duct of a liver of the mammalian subject a construct comprising a DNA of interest that encodes the desired polypeptide and a promoter sequence operably linked to the DNA of interest to facilitate expression in a eukaryotic cell; wherein the introduced construct is expressed in each of the salivary gland and the liver such that the polypeptide is delivered into the bloodstream of the mammal from each of the salivary gland and the liver. 7. The method of claim 6, wherein the DNA of interest encodes a factor VIII polypeptide. 8. The method of claim 6, wherein the DNA of interest encodes a erythropoietin polypeptide. 9. The method of claim 6, wherein introduction into the salivary gland and into the liver is by retrograde ductal administration. 10. The method of claim 6, wherein the construct introduced into the salivary gland is not contained within a viral particle. 11. A method of delivering a polypeptide to a mammalian subject, the method comprising: introducing in vivo into a lumen of a duct of a salivary gland and into a lumen of a duct of a pancreas of the mammalian subject a construct comprising a DNA of interest that encodes a desired polypeptide and a promoter sequence operably linked to the DNA of interest to facilitate expression in a eukaryotic cell; wherein the introduced construct is expressed in each of the salivary gland and the pancreas such that the polypeptide is delivered into the bloodstream of the mammalian subject from each of the salivary gland and the pancreas. 12. The method of claim 11, wherein the desired polypeptide is selected from the group consisting of insulin, growth hormone, interferon-alpha 2b, Interferon-alpha 2a, interferon-alpha N1, filgastim, insulinotropin, imiglucerase, clotting factor VIII, interferon-beta1b, erythropoietin, sargramostim, interleukin-2, interferon-gamma, anti-CD3 antibody, GPIIb/IIIa monoclonal antibody, adenosine deaminase, interleukin-8, insulin-like growth factor-1, platelet-derived growth factor, epidermal growth factor, and hemoglobin. 13. The method of claim 11, wherein the DNA of interest encodes a human insulin polypeptide. 14. The method of claim 11, wherein the DNA of interest encodes a factor VIII polypeptide. 15. The method of claim 11, wherein the DNA of interest encodes a crythropoietin polypeptide. 16. The method of claim 11, wherein introduction into the salivary gland and into the pancreas is by retrograde ductal administration. 17. The method of claim 11, wherein the construct introduced into the salivary gland is not contained within a viral particle. 18. A method of delivering a polypeptide to a mammalian subject, the method comprising: administering directly in vivo into a lumen of a duct of a pancreas and into a lumen of a duct of a liver of the mammalian subject a construct comprising a DNA of interest that encodes a desired polypeptide and a promoter sequence operably linked to the DNA of interest to facilitate expression in a eukaryotic cell; wherein the introduced construct is expressed in each of the pancreas and the liver such that the polypeptide is delivered into the bloodstream of the mammal from each of the pancreas and the liver. 19. The method of claim 18, wherein the desired polypeptide is selected from the group consisting of insulin, growth hormone, interferon-alpha 2b, Interferon-alpha 2a, interferon-alpha N1, filgastim, insulinotropin, imiglucerase, clotting factor VIII, interferon-beta1b, erythropoietin, sargramostim, interleukin-2, interferon-gamma, anti-CD3 antibody, GPIIb/IIIa monoclonal antibody, adenosine deaminase, interleukin-8, insulin-like growth factor-1, platelet-derived growth factor, epidermal growth factor, and hemoglobin. 20. The method of claim 18, wherein the DNA of interest encodes a human insulin polypeptide. 21. The method of claim 18, wherein the DNA of interest encodes a factor VIII polypeptide. 22. The method of claim 18, wherein the DNA of interest encodes an crythropoietin polypeptide. 23. The method of claim 18, wherein said administering is by retrograde ductal administration. 24. The method of claim 18, wherein said administering is by injection. 25. The method of claim 18, wherein said administering is by cannulation. 26. The method of claim 25, wherein said cannulation is by inserting a cannula through a lumen of the gastrointestinal tract. 27. The method of claim 25, wherein said cannulation is through an external orifice. 28. The method of claim 25, wherein said cannulation is by inserting a cannula through a common bile duct, wherein the DNA construct is delivered directly into the hepatic duct and into the pancreatic duct. 29. The method of claim 18, wherein the introduced construct is expressed in each of the pancreas and the liver such that the level of polypeptide in pancreatic tissue is elevated relative to a level of polypeptide in pancreatic tissue after delivery of the same amount of the construct in the same manner to pancreas alone. 30. The method of claim 6, wherein the desired polypeptide is selected from the group consisting of insulin, growth hormone, interferon-alpha 2b, Interferon-alpha 2a, interferon-alpha N1, filgastim, insulinotropin, imiglucerase, clotting factor VIII, interferon-beta1b, erythropoietin, sargramostim, interleukin-2, interferon-gamma, anti-CD3 antibody, GPIIb/IIIa monoclonal antibody, adenosine deaminase, interleukin-8, insulin-like growth factor-1, platelet-derived growth factor, epidermal growth factor, and hemoglobin. 31. The method of claim 6, wherein the DNA of interest encodes a human insulin polypeptide.

Details for Patent 6,004,944

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	05/23/1994		2015-03-24
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367	09/22/1999		2015-03-24
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2015-03-24
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2015-03-24